Grifols, S.A. (NASDAQ:GRFS) Receives $10.00 Average PT from Brokerages

Shares of Grifols, S.A. (NASDAQ:GRFS) have been assigned a consensus recommendation of “Hold” from the five brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $10.00.

A number of equities research analysts recently weighed in on GRFS shares. Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 15th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Thursday, January 22nd. JPMorgan Chase & Co. reduced their price target on shares of Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Finally, Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, December 5th.

Grifols Trading Up 1.0%

Shares of Grifols stock opened at $9.28 on Friday. The company has a quick ratio of 0.93, a current ratio of 2.48 and a debt-to-equity ratio of 1.20. Grifols has a 1-year low of $6.19 and a 1-year high of $11.14. The business’s fifty day moving average price is $9.10 and its two-hundred day moving average price is $9.47.

Institutional Trading of Grifols

A number of hedge funds and other institutional investors have recently modified their holdings of GRFS. Allworth Financial LP boosted its stake in Grifols by 15.7% during the fourth quarter. Allworth Financial LP now owns 8,073 shares of the biotechnology company’s stock valued at $75,000 after buying an additional 1,096 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Grifols by 2.4% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,192 shares of the biotechnology company’s stock valued at $427,000 after acquiring an additional 1,114 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Grifols by 25.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,928 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 1,212 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Grifols by 39.5% in the 3rd quarter. Versant Capital Management Inc now owns 5,598 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 1,584 shares during the last quarter. Finally, Merit Financial Group LLC raised its holdings in shares of Grifols by 14.1% in the 3rd quarter. Merit Financial Group LLC now owns 13,978 shares of the biotechnology company’s stock worth $139,000 after purchasing an additional 1,728 shares in the last quarter.

About Grifols

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.